# Cross-sectional and Longitudinal Relationship between Sex Hormones and Six Epigenetic Clocks in Older Adults: Results of the Berlin Aging Study II (BASE-II)

Hannah Schmid<sup>1</sup>, Valentin Max Vetter<sup>1</sup>, Jan Homann<sup>2</sup>, Vivien Bahr<sup>1</sup>, Christina M. Lill<sup>2,3</sup>, Vera Regitz-Zagrosek<sup>4,5</sup>, Lars Bertram<sup>6</sup>, Ilja Demuth<sup>1,7</sup>

<sup>1</sup>Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Endocrinology and Metabolic Diseases (including Division of Lipid Metabolism), Biology of Aging working group, Augustenburger Platz 1, 13353 Berlin, Germany

<sup>2</sup>Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany

<sup>3</sup>Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College London, London, UK

<sup>4</sup>Institute for Gender in Medicine, Center for Cardiovascular Research, Charité -Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt -Universität zu Berlin and Berlin Institute of Health, Berlin, Germany

<sup>5</sup>Department of Cardiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland

<sup>6</sup>Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), University of Lübeck, Lübeck, Germany

<sup>7</sup>Charité - Universitätsmedizin Berlin, BCRT - Berlin Institute of Health Center for Regenerative Therapies, Berlin, Germany

# **Corresponding author:**

Ilja Demuth (Ph.D.) Charité - Universitätsmedizin Berlin Lipid Clinic at the Interdisciplinary Metabolism Center, **Biology of Aging Group** Augustenburger Platz 1 13353 Berlin Email: ilja.demuth@charite.de Phone: ++49 30 450 569 143 FAX: ++49 30 450 566 904 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### Abstract

**Background** Beyond their essential roles in regulating reproduction and development, sex hormones play a crucial role in the aging processes. Observational studies have indicated that low sex hormone concentrations in older age are associated with adverse health events. DNA methylation age acceleration (DNAmAA) estimated from epigenetic clocks quantifies differences in biological aging. DNAmAA was previously shown to be associated with age at menopause, ovariectomy, hormone replacement therapy and testosterone level.

**Methods** We analysed the relationship between estradiol, dehydroepiandrosterone sulfate (DHEAS) and the Free Androgen Index (FAI) with DNAmAA estimators from six epigenetic clocks (Horvath's, Hannum's, 7-CpG clock, PhenoAge, GrimAge, DunedinPACE) in 1,404 participants of the Berlin Aging Study II (BASE-II, mean age at baseline  $68.7 \pm 3.7$  years, 48% women). The relationship was investigated in multiple linear regression models cross-sectionally at two time points and longitudinally over on average 7.3 years of follow-up.

**Results** We did not observe any consistent associations between the sex hormones and DNAmAA estimators investigated. However, we found several nominal associations (alpha=0.05) of unclear relevance. For instance, we identified an inverse association between DHEAS and Horvath's DNAmAA, i.e. a reduced biological age with higher DHEAS levels in men at baseline. In women we found an inverse association between estradiol and DunedinPACE (baseline) and a positive association with GrimAge (follow-up). In longitudinal analyses,  $\Delta$ DHEAS and  $\Delta$ DunedinPACE were inversely associated in both sexes.

**Conclusions** Our results suggest that sex hormones play at best a minor role with respect to biological aging in the older population studied here.

# Introduction

Biological aging refers to differences in the aging process in people of the same chronological age. One of the latest and most promising biomarker of aging is the DNA methylation age (DNAmA) and its deviation from chronological age, DNAmA acceleration (DNAmAA) <sup>1,2</sup>, which are calculated from DNA methylation data by epigenetic clock algorithms.

To date, numerous epigenetic clocks are available that mostly differ in the way they were developed and the number and location of cytosine-phosphate-guanine (CpG) sites they include <sup>3-8</sup>. Previous analyses showed differences in the clock's ability to predict morbidity and agerelated pathologies independent of chronological age <sup>1,9,10</sup>. First generation clocks such as Horvath's, Hannum's and the 7-CpG clock are designed to predict chronological age <sup>3-5</sup>. Second generation clocks like GrimAge and PhenoAge are highly correlated with age associated pathologies and lifespan <sup>6,7</sup>. DunedinPACE, a third generation clock, is designed to capture an individual's pace of aging as well as differences from a normal aging rate <sup>8</sup>.

Sex hormones have been recognised as factors involved in the aging processes, in addition to their essential function in regulating reproduction and development <sup>11,12</sup>. In general, estrogens such as estradiol are distinguished from gestagens and androgens including testosterone and dehydroepiandrosterone sulfate (DHEAS). Over the life course, humans experience profound changes in sex hormone concentrations <sup>12</sup>. In women, estradiol declines rapidly to approximately 20% of its maximum premenopausal concentration after the menopause <sup>13</sup>. In contrast, the testosterone concentration in men peaks around the age of thirty followed by a gradual decrease of one to two percent per year <sup>14</sup>. In both sexes, the DHEAS level decreases slowly starting in the third decade and resulting in a reduction by approximately 80% of its maximum around the seventh decade <sup>15</sup>. The close temporal association between the decline in sex hormones and the age-related loss of physical abilities suggests a causal interaction <sup>12</sup>. This assumption is further supported by findings from observational studies that indicate an

association of low sex hormone concentrations in older age with adverse health events <sup>16-18</sup>. Some studies suggest that the decline in DHEAS is associated with a higher mortality risk in men <sup>19,20</sup>. DHEAS was referred to as an "anti-aging hormone" <sup>21</sup> and is available as an over-the-counter supplement in some countries although there is no consensus on its effectiveness <sup>22</sup>. Low levels of testosterone were suggested as a risk factor for short- and long-term mortality in older men <sup>23-25</sup>. In older women, a long reproductive period and late onset of menopause are related to longevity and reduced risk of mortality <sup>26-28</sup>. Premature loss of ovarian estrogens is associated with multimorbidity, while estrogen substitution showed protective effects <sup>29</sup>.

Because of these properties and associations, the relationship of sex hormones and biological age is of high interest. Since effects of sex hormones on overall DNAm levels were shown before, an association of sex hormone concentrations and DNAmAA seems biologically plausible <sup>30,31</sup>. Indeed, studies in mice showed an accelerated epigenetic age after ovariectomy <sup>32</sup> and in postmenopausal women, associations between early age at menopause and higher GrimAge and Horvath's DNAmAA have been reported <sup>7,33</sup>. Furthermore, Levine and colleagues suggested that biological aging processes accelerate when women enter the post-reproductive phase and that postmenopausal use of hormone replacement therapy (HRT) decreases epigenetic age in some tissues <sup>33</sup>. A recent study found an inverse association between GrimAge and PhenoAge DNAmAA, respectively, and testosterone in men <sup>34</sup>. Since stronger associations were reported for bioavailable testosterone <sup>34</sup>, we used the Free Androgen Index (FAI) as an indicator of the free, SHBG-unbound proportion of testosterone in our study <sup>35</sup>.

Despite these initial findings suggesting an association between sex hormones and DNAmAA, their potential cross-sectional and longitudinal relationship at different time points has not been studied yet. Thus, the objective of this study was to analyse the relationship between sex hormones (estradiol, DHEAS and the FAI) with DNAmAA estimators employing six different epigenetic clocks at two time points about seven years apart and to investigate the change of

these variables over the observation period. Based on the previously reported results discussed above, we hypothesised that sex hormone concentrations are inversely associated with DNAmAA and that the association is also reflected in our longitudinal data.

#### Methods

# Study population

Participants of the Berlin Aging Study II (BASE-II) cohort were recruited from the greater metropolitan area of Berlin, Germany. The multidisciplinary BASE-II aims to identify mechanisms and factors contributing to a healthy aging process. A subsample consisting of 1,671 older participants (aged  $\geq$ 60 years) from the BASE-II were medically assessed at baseline between 2009 and 2014 <sup>36</sup>. As part of the GendAge study, 1083 participants were reassessed with a mean follow-up time of 7.4 years (SD=1.5) between 2018 and 2020 <sup>37</sup>. Cohort characteristics are shown in Table 1 and Supplementary Table 1.

# Sample selection

Composition of participant numbers and final analytical datasets at baseline and follow-up are represented in Figure 1. The follow-up data set comprises 17 additional participants who were not medically examined in the baseline assessment. Women who reported taking oral or transdermal estrogen-containing HRT within one year prior to the baseline assessment were excluded from the baseline and longitudinal analyses. At follow-up no information on HRT cessation was available. Following the maximum duration of HRT recommended in the literature, we did not exclude women from the follow-up analyses <sup>38</sup>. DHEAS data of three men and one woman were excluded from the baseline dataset due to extremely high values (> 7 SD from the mean).

# DNA Methylation Data

Estimation of DNAmA was based on three first-generation (Horvath's <sup>3</sup>, Hannum's <sup>4</sup>, 7-CpG clock <sup>5</sup>), two second-generation (PhenoAge <sup>6</sup>, GrimAge <sup>7</sup>) and one third-generation epigenetic clock (DunedinPACE <sup>8</sup>). DNAm data originated from leukocyte DNA from whole blood samples drawn at baseline and follow-up assessment. Blood samples for sex hormone

measurement were taken from the same blood draws. Methylation data was obtained using two methods. For Horvath's <sup>3</sup>, Hannum's <sup>4</sup>, PhenoAge <sup>6</sup>, GrimAge <sup>7</sup> methylation age and DunedinPACE <sup>8</sup>, methylation data was measured with the "Infinium MethylationEPIC" array (Illumina, Inc., USA). Detailed information about the sample handling and data processing were reported before <sup>39</sup>. DunedinPACE was calculated as instructed in the original publication <sup>8</sup>. A more detailed description of the methods can be found in ref. <sup>39</sup>. For the 7-CpG clock measurement <sup>40</sup>, DNAm data was obtained using methylation-sensitive single nucleotide primer extension (MS-SNuPE). For a detailed description of the laboratory protocol see reference <sup>5,40</sup>. DNAmAA was calculated as the unstandardized residual resulting from regressing calculated DNAmA on chronological age while adjusting for blood cell counts (neutrophils, monocytes, lymphocytes, eosinophils) <sup>9,40</sup>. Blood cell composition was measured by an accredited laboratory (Labor Berlin GmbH, Berlin, Germany) using flow cytometry.

### Sex hormones

Blood was drawn from all participants after an >8h fasting period and kept at 4–8 °C until analysis on the same day. Sex hormones were measured in serum samples by an accredited laboratory (Labor Berlin GmbH, Berlin, Germany) using fluoro- (estradiol, total testosterone (TT)), radio- (DHEAS) and chemiluminescentimmunoassays (sex hormone-binding globulin (SHBG)). During the study period, laboratory methods for measurement of sex hormones changed to electrochemiluminescence immunoassays (ECLIA). For further details we refer to the Supplementary Methods. In the final dataset, n=152 (estradiol, TT and SHBG) and n=39 (DHEAS) participants were affected by the change. A comparison of methods conducted by the accredited laboratory showed a high degree of comparability between the methods used ( $R^2$ =0.95 and 0.97, data not shown). The FAI was calculated by using the formula: TT (nmol/l) × 100 / SHBG (nmol/l) <sup>35</sup>.

### Covariates

Covariates were selected based on commonly employed factors within the field <sup>34</sup>. Smoking behaviour was assessed in pack years during a one-on-one interview by trained study personnel. Daily intake of alcohol (g/d) was assessed using the European Prospective Investigation into Cancer and Nutrition Food Frequency Questionnaire (EPIC-FFQ) <sup>41</sup>. Body Mass Index (BMI, kg/m2) was calculated from height and weight measured with an electronic measuring station (seca 763 measuring station, SECA, Germany). Information on menopausal status, medication and use of HRT, including initiation and cessation of HRT, were self-reported and based on medical reports when available.

#### Statistical analysis

Statistical analyses were carried out using the IBM SPSS software package (IBM Corp. Released 2023. IBM SPSS Statistics for Windows, Version 29.0.2.0 Armonk, NY: IBM Corp). To account for sex-dependent hormone profiles, all statistical procedures were carried out in sex-stratified subgroups. Distribution of sex hormone data was visually inspected and found to be skewed. Therefore, non-parametric tests were conducted. Spearman correlation coefficients were calculated. The DNAmAA estimators were treated as a dependent variable in the multiple linear regression analyses. Linear regression models were adjusted for chronological age, BMI, pack years and alcohol intake (g/d). For longitudinal analyses, change in DNAmAA and sex hormones (denoted by  $\Delta$ variable) was calculated as the difference between values at follow-up and baseline examination and found to be normally distributed. Pearson correlation coefficients were calculated. Linear regression analyses of  $\Delta$ DNAmAA on  $\Delta$ sex hormones were adjusted for baseline variables (chronological age, sex hormone concentration, DNAmAA, pack years, alcohol intake (g/d), BMI and years since baseline assessment). Only participants with no missing values in the variables included in the respective analyses were considered (available case analysis). This resulted in varying numbers of complete cases depending on the clock and

hormone analysed. A p-value below 0.05 was considered as statistically significant. Due to the

explorative character of the study we did not correct for multiple testing.

### Results

# **Descriptive Statistics**

The baseline sample consisted of 1,404 participants (48% women). As part of the follow-up examination 1,015 participants (49% women) were reassessed on average 7.3 years (SD=1.5) later. The mean age at baseline was 68.4 years (SD=3.6) for women and 69.0 years (SD=3.8) for men. At baseline all women were postmenopausal with a mean interval of 18.7 years since menopause (SD=7.3, n=668) and 49.7 (SD=6.0) years as the average age at menopause. In men and women, median DHEAS concentration and the FAI decreased significantly between the assessments (Wilcoxon signed-rank test, p<0.001, Table 2). An increase in median estradiol concentration was found among men (p<0.001). A statistically significant increase in GrimAge DNAmAA by 0.38 years was shown for men (paired t-test p<0.001, Table 2), while GrimAge a significantly by 0.33 years in women (p=0.004). In both sexes, there was a significant increase in DunedinPACE by 0.07 years (p<0.001).

# Cross-sectional analyses: baseline

Baseline analyses indicated weak correlations (Spearman's rho) between sex hormones and DNAmAA estimators ranging from r=-0.06 to 0.13 for men and from r=-0.07 to 0.10 for women (Supplementary Table 2). After adjustment for potential confounders an inverse association of DHEAS with Horvath's DNAmAA ( $\beta$ =-0.0007, p=0.032, Table 3) was found in linear regression analyses for men. To illustrate, a decrease in Horvath's DNAmAA by 0.45 years for every increase in DHEAS of one SD was observed. In women, estradiol was inversely associated with DunedinPACE ( $\beta$ =-0.0004, p=0.032, Table 3). Every one SD increase in estradiol was associated with a 0.01 year decrease in DunedinPACE. Cross-sectional analyses on the baseline dataset revealed no further relevant associations (see Supplementary Table 3).

#### Cross-sectional analyses: follow-up

Similar to baseline analyses, weak correlations were found between follow-up DNAmAA estimators and sex hormone level ranging from r=-0.11 to 0.10 for men and r=-0.08 to 0.09 for women (Supplementary Table 2). Adjusted linear regression analyses for women revealed a weak positive association between estradiol and the GrimAge DNAmAA ( $\beta$ =0.002, p=0.036, Supplementary Table 4). All other cross-sectional analyses on the follow-up dataset did not show any recurrent associations between sex hormones and DNAmAA (see Supplementary Table 4).

#### Longitudinal analyses

To assess whether changes in sex hormone concentrations were related to changes in DNAmAA over the follow-up period, we conducted longitudinal analyses. Weak significant correlation coefficients (Pearson) were found between  $\Delta$ DHEAS and  $\Delta$ DunedinPACE for men (r=-0.18, p<0.001) and women (r=-0.11, p=0.018, Supplementary Table 2 and Supplementary Figure 1). After covariate adjustment  $\Delta$ DHEAS showed an inverse association with  $\Delta$ DunedinPACE in linear regression analyses for both men ( $\beta$ =-0.00002, p=0.022, Table 4) and women ( $\beta$ =-0.00003, p=0.005). Each one SD increase in DHEAS concentration over the assessment period was associated with a decrease in the pace of aging of 0.009 (men) and 0.01 (women) years, respectively, as measured by DunedinPACE. No further noteworthy associations were found between  $\Delta$ DNAmAA and  $\Delta$ sex hormone levels (see Supplementary Table 5). Additionally, we conducted a subgroup analysis of participants who experienced a longitudinal hormone decline greater than the median (Supplementary Table 6). Here, no substantial differences from the overall findings were observed.

# Discussion

In this study, we investigated the relationship between estradiol, DHEAS and the FAI with biological age estimated from first-, second- and third-generation epigenetic clocks in cross-sectional and longitudinal data of BASE-II participants aged  $\geq 60$  years. Generally, no consistent and clinically relevant relationship was found between any of the sex hormones and DNAmAA estimators analysed in this study. Despite this overall lack of significant relationships we observed several nominal associations of unclear relevance. For instance, we identified a weak inverse association between DHEAS and Horvath's DNAmAA in men at baseline. For women we found weak inverse associations between estradiol and DunedinPACE (baseline) and positive associations with GrimAge (follow-up). In longitudinal analyses, there was a weak inverse association between  $\Delta$ DHEAS and  $\Delta$ DunedinPACE, which was present in both sexes.

To date, only one study has assessed the relationship between epigenetic clocks as measures of biological aging and sex hormones. In that study by Kusters and colleagues, data of three population-based cohorts of similar age compared to the group of older BASE-II participants were examined cross-sectionally <sup>34</sup>. They found that higher testosterone was associated with lower GrimAge and PhenoAge DNAmAA in men. For six more age acceleration measures they did not find significant associations <sup>34</sup>. Regarding the age-related reduction in testosterone in men, studies found that lower testosterone levels were associated with increased mortality risk in older age <sup>23-25,42</sup>. Testosterone replacement in testosterone deficient men, on the other hand, decreased mortality <sup>43,44</sup>. Supporting this direction of effect, Kusters and colleagues suggested that the adverse health outcomes associated with lower testosterone might be moderated by accelerated epigenetic aging <sup>34</sup>. While, in our fully adjusted models, we could not replicate this finding, the direction of the (non-significant) relationship of the FAI with GrimAge and DunedinPACE was in line with the results reported by Kusters and colleagues.

In our study, we observed an inverse association between estradiol and DunedinPACE in women at baseline, whereas at follow-up, estradiol levels were positively associated with the GrimAge clock. Given the inconsistent associations observed across our analyses and the small effect sizes, we consider it unlikely that these findings have relevant clinical implications. Furthermore, the lack of a meaningful relationship between estradiol and the DNAmAA estimators investigated here suggests that estradiol may not be a major driver of the accelerated rate of biological aging in women after the menopause <sup>33</sup>. Regarding higher postmenopausal estradiol levels and the use of HRT, both health benefits and risks have been reported <sup>45-47</sup>. Studies also suggested that survival benefits of postmenopausal HRT may diminish over time <sup>48</sup>. Thus, while estradiol's influence on aging is complex, our results do not support a strong role for estradiol in mediating these effects through the DNAmAA mechanisms in the older women studied here.

The reputation of DHEAS as an anti-aging hormone stems from studies that have found a higher mortality risk <sup>19,49,50</sup> and a reduced physical capacity in association with lower DHEAS levels <sup>19,51</sup>. Fahy and colleagues published a study on epigenetic age reversal involving DHEA supplementation suggesting a potential positive impact of higher DHEAS levels on biological aging <sup>52</sup>. Therefore, we assumed an inverse association to be present in our data. Indeed, we found higher DHEAS levels associated with slower epigenetic aging as measured by Horvath's clock in cross-sectional analyses in men. With each one SD increase in DHEAS, Horvath's DNAmAA decreased by 0.45 years. Also, participants of both sexes exhibiting an increase in DHEAS concentration of one SD over the assessment period of on average 7.3 years, decreased in their pace of aging (DunedinPACE) by 0.009 and 0.01 years, respectively. Our findings suggest that increases in DHEAS levels are associated with a slightly slower rate of biological aging (DunedinPACE and Horvath's DNAmAA) thereby supporting the direction of an effect

reported before. However, the effect size estimate was relatively small, and additional research would be needed to further investigate clinical relevance and potential underlying mechanisms.

We note that the lack of consistent associations in this study does not necessarily exclude the presence of a relationship between sex hormone levels and DNAmAA. The lack of noteworthy findings may also be due to one or several of the limitations of our study. First, we were not able to investigate bioavailable hormones due to lack of albumin measurement at follow-up. However, as a proxy and commonly used parameter to estimate the unbound testosterone fraction we used the FAI in our study <sup>35</sup>. Second, around a third of the baseline participants were not followed up, which possibly introduces a selection bias. However, a comparison of sex hormone levels between participants with baseline and follow-up data and those lost to follow-up revealed no statistically significant differences, except that the dropout group had a higher average age (Supplementary Table 7). Third, despite the fact that with n=1,404 our sample size was relatively large, we cannot exclude the possibility that the lack of significant findings may be due to insufficient power, especially to detect small effects. Finally, as previously reported, the study population investigated here tends to have an above-average health status, which limits the generalisability of the results to the general population.

Strengths of this study include the availability of six different epigenetic clocks and four sex hormones at two time points with a mean follow-up time of 7.3 years. This allowed us to investigate the long-term relationships between sex hormones and DNAmAA, in addition to cross-sectional analyses, which was not done before. Moreover, due to the detailed information on hormone intake and medication, it was possible to exclude participants who were taking exogenous sex hormones. Information on potentially confounding factors such as BMI, cigarette smoking and alcohol intake were available, which allowed us to control for these factors.

The age-related decline in sex hormones has substantial implications for the health and quality of life in the older population. Our study provides explorative insights into the cross-sectional and longitudinal relationship between sex hormones and DNAmAA in older adults. Future studies with longitudinal measurements of sex hormones and DNAmAA in a study population that includes participants at the age of hormonal transition are needed to further investigate the relationship between biological aging and sex hormone levels.

## Conclusion

In this study, we cross-sectionally and longitudinally investigated the relationship between epigenetic clocks and sex hormones in 1,404 participants aged  $\geq$ 60 years over a 7.3-year follow-up period. Generally, we did not observe a consistent relationship between estradiol, DHEAS, the FAI and epigenetic age as assessed by six different DNAmAA estimators. This suggests that sex hormones play at best a minor role with respect to biological aging in the older population studied here.

# Acknowledgments

This work was supported by grants of the Deutsche Forschungsgemeinschaft (project number 460683900 to ID & LB), the ERC (as part of the Lifebrain project to LB), and the Cure Alzheimer's Fund (as part of the CIRCUITS consortium to LB). Additional funds supporting this research came from a grant of the EU Joint Programme – Neurodegenerative Disease Research (project EPIC4ND, coordination: C.M.L.). This article uses data from the Berlin Aging Study II (BASE-II) and the GendAge study, which were supported by the German Federal Ministry of Education and Research under grant numbers #01UW0808; #16SV5536K, #16SV5537, #16SV5538, #16SV5837, #01GL1716A and #01GL1716B. We thank all probands of the BASE-II/GendAge study for their participation in this research. C. M. L. was supported by the Heisenberg programme of the German Research Foundation (DFG; LI 2654/4-1).

#### **Author contributions**

Conceived and designed the study: HS, VMV and ID. Contributed study-specific data: VMV, JH, VRZ, LB, and ID. Analysed the data: HS. Wrote the manuscript: HS, VMV and ID. All authors revised and approved the manuscript.

# **Competing interests**

The authors declare no competing interests.

#### Data availability statement

Due to concerns for participant privacy, data are available only upon reasonable request. Please contact Ludmila Müller, scientific coordinator, at lmueller@mpib-berlin.mpg.de, for additional information.

# **Ethics**

All participants gave written informed consent. Medical assessments were conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Charité – Universitaetsmedizin Berlin (approval numbers EA2/029/09 and EA2/144/16) and were registered in the German Clinical Trials Registry as DRKS00009277 and DRKS00016157.

## References

1. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. *Nat Rev Genet*. Jun 2018;19(6):371-384. doi:10.1038/s41576-018-0004-3

Jylhava J, Pedersen NL, Hagg S. Biological Age Predictors. *EBioMedicine*. Jul 2017;21:29-36.
 doi:10.1016/j.ebiom.2017.03.046

3. Horvath S. DNA methylation age of human tissues and cell types. Genome biology: Genome Biol; 2013. doi:10.1186/GB-2013-14-10-R115

4. Hannum G, Guinney J, Zhao L, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. *Mol Cell*. Jan 24 2013;49(2):359-367. doi:10.1016/j.molcel.2012.10.016

5. Vetter VM, Kalies CH, Sommerer Y, Bertram L, Demuth I. Seven-CpG DNA Methylation Age Determined by Single Nucleotide Primer Extension and Illumina's Infinium MethylationEPIC Array Provide Highly Comparable Results. *Front Genet*. 2021;12:759357. doi:10.3389/fgene.2021.759357

6. Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan. *Aging (Albany NY)*. Apr 18 2018;10(4):573-591. doi:10.18632/aging.101414

7. Lu AT, Quach A, Wilson JG, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. *Aging (Albany NY)*. Jan 21 2019;11(2):303-327. doi:10.18632/aging.101684

8. Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. *Elife*. Jan 14 2022;11. doi:10.7554/eLife.73420

9. Chen BH, Marioni RE, Colicino E, et al. DNA methylation-based measures of biological age: meta-analysis predicting time to death. *Aging (Albany NY)*. Sep 28 2016;8(9):1844-1865. doi:10.18632/aging.101020

10. Oblak L, van der Zaag J, Higgins-Chen AT, Levine ME, Boks MP. A systematic review of biological, social and environmental factors associated with epigenetic clock acceleration. *Ageing Res Rev.* Aug 2021;69:101348. doi:10.1016/j.arr.2021.101348

11. Horstman AM, Dillon EL, Urban RJ, Sheffield-Moore M. The role of androgens and estrogens on healthy aging and longevity. *J Gerontol A Biol Sci Med Sci*. Nov 2012;67(11):1140-52. doi:10.1093/gerona/gls068

18

Lamberts SW, van den Beld AW, van der Lely AJ. The endocrinology of aging. *Science*. Oct
 17 1997;278(5337):419-24. doi:10.1126/science.278.5337.419

13. Chakravarti S, Collins WP, Forecast JD, Newton JR, Oram DH, Studd JW. Hormonal profiles after the menopause. *Br Med J*. Oct 2 1976;2(6039):784-7. doi:10.1136/bmj.2.6039.784

Decaroli MC, Rochira V. Aging and sex hormones in males. *Virulence*. Jul 4 2017;8(5):545 570. doi:10.1080/21505594.2016.1259053

15. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. *J Clin Endocrinol Metab*. Sep 1984;59(3):551-5. doi:10.1210/jcem-59-3-551

16. Forti P, Maltoni B, Olivelli V, Pirazzoli GL, Ravaglia G, Zoli M. Serum dehydroepiandrosterone sulfate and adverse health outcomes in older men and women. *Rejuvenation Res.* Aug 2012;15(4):349-58. doi:10.1089/rej.2011.1248

17. Wang Y, Islam RM, Hussain SM, McNeil JJ, Davis SR. Associations Between Blood Concentrations of Sex Hormones and Physical Function in Community-Dwelling Older Women: A Prospective Cohort Study. Gerontol A Biol Sci Med Sci. JApr 1 2024;79(4). doi:10.1093/gerona/glad287

18. Islam RM, Bell RJ, Handelsman DJ, et al. Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial. *Lancet Healthy Longev*. Feb 2022;3(2):e109-e118. doi:10.1016/S2666-7568(22)00001-0

19. Berr C, Lafont S, Debuire B, Dartigues JF, Baulieu EE. Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study. *Proc Natl Acad Sci U S A*. Nov 12 1996;93(23):13410-5. doi:10.1073/pnas.93.23.13410

20. Li R, E L, Zha N. Circulating dehydroepiandrosterone sulfate level and cardiovascular or allcause mortality in the elderly population: a meta-analysis. *Ann Palliat Med*. Sep 2020;9(5):3537-3545. doi:10.21037/apm-20-441

21. Nawata H, Yanase T, Goto K, Okabe T, Ashida K. Mechanism of action of anti-aging DHEA-S and the replacement of DHEA-S. *Mech Ageing Dev*. Apr 30 2002;123(8):1101-6. doi:10.1016/s0047-6374(01)00393-1

22. Arlt W. Dehydroepiandrosterone and ageing. *Best Pract Res Clin Endocrinol Metab*. Sep 2004;18(3):363-80. doi:10.1016/j.beem.2004.02.006

23. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. *J Clin Endocrinol Metab.* Jan 2008;93(1):68-75. doi:10.1210/jc.2007-1792

24. Tivesten A, Vandenput L, Labrie F, et al. Low serum testosterone and estradiol predict mortality in elderly men. *J Clin Endocrinol Metab.* Jul 2009;94(7):2482-8. doi:10.1210/jc.2008-2650

25. Wang J, Fan X, Yang M, et al. Sex-specific associations of circulating testosterone levels with all-cause and cause-specific mortality. *Eur J Endocrinol*. May 2021;184(5):723-732. doi:10.1530/EJE-20-1253

26. Shadyab AH, Macera CA, Shaffer RA, et al. Ages at Menarche and Menopause and Reproductive Lifespan As Predictors of Exceptional Longevity in Women: The Women's Health Initiative HHS Public Access. Menopause2017. p. 35-44. doi:10.1097/GME.000000000000710

27. Ossewaarde ME, Bots ML, Verbeek ALM, et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology2005. p. 556-562. doi:10.1097/01.EDE.0000165392.35273.D4

 Jacobsen BK, Heuch I, Kvåle G. Age at Natural Menopause and All-Cause Mortality: A 37-Year Follow-up of 19,731 Norwegian Women. American Journal of Epidemiology: Oxford Academic;
 2003. p. 923-929. doi:10.1093/AJE/KWG066

29. Rocca WA, Gazzuola-Rocca L, Smith CY, et al. Accelerated Accumulation of Multimorbidity After Bilateral Oophorectomy: A Population-Based Cohort Study. Mayo Clinic proceedings: NIH Public Access; 2016. p. 1577. doi:10.1016/J.MAYOCP.2016.08.002

30. Harbs J, Rinaldi S, Keski-Rahkonen P, et al. An epigenome-wide analysis of sex hormone levels and DNA methylation in male blood samples. *Epigenetics*. Dec 2023;18(1):2196759. doi:10.1080/15592294.2023.2196759

31. Hilser JR, Hartiala JA, Sriprasert I, et al. Effect of menopausal hormone therapy on methylation levels in early and late postmenopausal women. *Clin Epigenetics*. Jul 18 2022;14(1):90. doi:10.1186/s13148-022-01311-w

32. Stubbs TM, Bonder MJ, Stark AK, et al. Multi-tissue DNA methylation age predictor in mouse. *Genome Biol.* Apr 11 2017;18(1):68. doi:10.1186/s13059-017-1203-5

33. Levine ME, Lu AT, Chen BH, et al. Menopause accelerates biological aging. *Proc Natl Acad Sci U S A*. Aug 16 2016;113(33):9327-32. doi:10.1073/pnas.1604558113

34. Kusters CDJ, Paul KC, Lu AT, et al. Higher testosterone and testosterone/estradiol ratio in men are associated with decreased Pheno-/GrimAge and DNA-methylation based PAI1. *Geroscience*. Jun 27 2023. doi:10.1007/s11357-023-00832-3

35. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. *J Clin Endocrinol Metab*. Oct 1999;84(10):3666-72. doi:10.1210/jcem.84.10.6079

Bertram L, Böckenhoff A, Demuth I, et al. Cohort profile: The Berlin aging study II (BASE-II).
International Journal of Epidemiology2014. p. 703-712. doi:10.1093/ije/dyt018

37. Demuth I, Banszerus V, Drewelies J, et al. Cohort profile: Follow-up of a Berlin Aging Study
II (BASE-II) subsample as part of the GendAge study. BMJ Open2021. p. 6-8. doi:10.1136/bmjopen2020-045576

Martin KA, Manson JE. Approach to the patient with menopausal symptoms. *J Clin Endocrinol Metab.* Dec 2008;93(12):4567-75. doi:10.1210/jc.2008-1272

39. Vetter VM, Kalies CH, Sommerer Y, et al. Relationship Between 5 Epigenetic Clocks, Telomere Length, and Functional Capacity Assessed in Older Adults: Cross-Sectional and Longitudinal Analyses. *The Journals of Gerontology: Series A*. 2022;77(9):1724-1733. doi:10.1093/gerona/glab381

40. Vetter VM, Meyer A, Karbasiyan M, Steinhagen-Thiessen E, Hopfenmuller W, Demuth I. Epigenetic Clock and Relative Telomere Length Represent Largely Different Aspects of Aging in the Berlin Aging Study II (BASE-II). *J Gerontol A Biol Sci Med Sci*. Jan 1 2019;74(1):27-32. doi:10.1093/gerona/gly184

41. Nothlings U, Hoffmann K, Bergmann MM, Boeing H. Fitting portion sizes in a selfadministered food frequency questionnaire. *J Nutr.* Dec 2007;137(12):2781-6. doi:10.1093/jn/137.12.2781

42. Vikan T, Schirmer H, Njolstad I, Svartberg J. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromso Study. *Eur J Endocrinol*. Sep 2009;161(3):435-42. doi:10.1530/EJE-09-0284

43. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. *J Clin Endocrinol Metab*. Jun 2012;97(6):2050-8. doi:10.1210/jc.2011-2591

44. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. *Eur J Endocrinol*. Dec 2013;169(6):725-33. doi:10.1530/EJE-13-0321

45. La Vecchia C, Brinton LA, McTiernan A. Menopause, hormone replacement therapy and cancer. *Maturitas*. Aug 25 2001;39(2):97-115. doi:10.1016/s0378-5122(01)00213-4

46. Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. *Cochrane Database Syst Rev.* Mar 10 2015;2015(3):CD002229. doi:10.1002/14651858.CD002229.pub4

47. Maggio M, Ceda GP, Lauretani F, et al. Relationship between higher estradiol levels and 9-year mortality in older women: the Invecchiare in Chianti study. *J Am Geriatr Soc*. Oct 2009;57(10):1810-5. doi:10.1111/j.1532-5415.2009.02464.x

48. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. *N Engl J Med.* Jun 19 1997;336(25):1769-75. doi:10.1056/NEJM199706193362501

49. Ohlsson C, Labrie F, Barrett-Connor E, et al. Low serum levels of dehydroepiandrosterone sulfate predict all-cause and cardiovascular mortality in elderly Swedish men. *J Clin Endocrinol Metab*. Sep 2010;95(9):4406-14. doi:10.1210/jc.2010-0760

50. Trivedi DP, Khaw KT. Dehydroepiandrosterone sulfate and mortality in elderly men and women. *J Clin Endocrinol Metab.* Sep 2001;86(9):4171-7. doi:10.1210/jcem.86.9.7838

51. Voznesensky M, Walsh S, Dauser D, Brindisi J, Kenny AM. The association between dehydroepiandosterone and frailty in older men and women. *Age Ageing*. Jul 2009;38(4):401-6. doi:10.1093/ageing/afp015

52. Fahy GM, Brooke RT, Watson JP, et al. Reversal of epigenetic aging and immunosenescent trends in humans. *Aging Cell*. Dec 2019;18(6):e13028. doi:10.1111/acel.13028

#### Table 1: Characteristics of the 1,404 BASE-II participants at baseline (T0) of which 1,015 were

Men			Women		
Mean	SD		Mean	SD	
Mdn	IQR	n	Mdn	IQR	n
69.02	3.78	731	68.41	3.58	673
75.50	4.01	514	75.66	3.55	501
7.02	1.37	514	7.63	1.46	501
5.00	21.25	702	0.00	6.69	652
12.73	21.30	717	5.32	10.65	656
27.25	3.61	727	26.54	4.69	668
84.45	53.49	725	9.20	33.89	667
1055.50	819.60	728	736.25	739.84	667
36.69	13.38	718	0.90	1.25	641
65.17	4.97	488	62.81	4.64	468
56.54	4.36	488	53.89	4.28	468
67.64	7.68	714	65.02	7.39	635
54.92	5.43	488	52.53	5.48	468
72.17	3.92	488	68.55	3.84	468
	Men Mean Mdn 69.02 75.50 7.02 5.00 12.73 27.25 84.45 1055.50 36.69 65.17 56.54 67.64 54.92 72.17	Men         SD           Mean         SD           Mdn         IQR           69.02         3.78           75.50         4.01           7.02         1.37           5.00         21.25           12.73         21.30           27.25         3.61           84.45         53.49           1055.50         819.60           36.69         13.38           65.17         4.97           56.54         4.36           67.64         7.68           54.92         5.43           72.17         3.92	$\begin{tabular}{ c c c c c } \hline Men & SD & & & & & & \\ \hline Mean & IQR & & & & & & \\ \hline Mdn & IQR & & & & & & \\ \hline 69.02 & 3.78 & 731 & & \\ \hline 75.50 & 4.01 & 514 & & \\ \hline 7.02 & 1.37 & 514 & & \\ \hline 5.00 & 21.25 & 702 & & \\ \hline 12.73 & 21.30 & 717 & & \\ \hline 27.25 & 3.61 & 727 & & \\ \hline 84.45 & 53.49 & 725 & & \\ \hline 1055.50 & 819.60 & 728 & & \\ \hline 36.69 & 13.38 & 718 & & \\ \hline 65.17 & 4.97 & 488 & & \\ \hline 56.54 & 4.36 & 488 & & \\ \hline 56.54 & 4.36 & 488 & & \\ \hline 56.54 & 7.68 & 714 & & \\ \hline 54.92 & 5.43 & 488 & & \\ \hline 72.17 & 3.92 & 488 & & \\ \hline \end{tabular}$	$\begin{tabular}{ c c c c c c c } \hline Men & SD & & Mean \\ \hline Mean & IQR & & Mdn \\ \hline 69.02 & 3.78 & 731 & 68.41 \\ \hline 75.50 & 4.01 & 514 & 75.66 \\ \hline 7.02 & 1.37 & 514 & 7.63 \\ \hline 5.00 & 21.25 & 702 & 0.00 \\ \hline 12.73 & 21.30 & 717 & 5.32 \\ \hline 27.25 & 3.61 & 727 & 26.54 \\ \hline 84.45 & 53.49 & 725 & 9.20 \\ \hline 1055.50 & 819.60 & 728 & 736.25 \\ \hline 36.69 & 13.38 & 718 & 0.90 \\ \hline \hline 65.17 & 4.97 & 488 & 62.81 \\ \hline 56.54 & 4.36 & 488 & 53.89 \\ \hline 67.64 & 7.68 & 714 & 65.02 \\ \hline 54.92 & 5.43 & 488 & 52.53 \\ \hline 72.17 & 3.92 & 488 & 68.55 \\ \hline \end{tabular}$	$\begin{array}{c c c c c c c c c c c c c c c c c c c $

reassessed on average 7.3 years later (T1) as included in the current analyses

Note. <sup>a</sup>=Median + Inter Quartile Range, SD=Standard Deviation, Mdn=Median, IQR= Inter

Quartile Range, FAI=Free Androgen Index, DNAmA=DNA methylation age (years).

	Men				Women					
	T0 (2009-2014)	T1 (2018-2020)			T0 (2009-2014)	T1 (2018-2020)				
Variables	Mean (SD)	Mean (SD)		p-value	Mean (SD)	Mean (SD)		p-value		
Variables	Mdn (IQR)	Mdn (IQR)	n		Mdn (IQR)	Mdn (IQR)				
DNAmAA (years)										
Horvath	0.62 (4.21)	0.46 (3.98)	443	0.258	-0.61 (4.07)	-0.54 (3.69)	400	0.651 <sup>b</sup>		
Hannum	0.71 (3.46)	0.81 (4.00)	443	0.414	-0.77 (3.31)	-0.74 (3.53)	400	0.794 <sup>b</sup>		
7-CpG clock	1.05 (6.86)	0.97 (5.49)	449	0.735	-1.22 (6.66)	-0.96 (5.30)	402	0.275 <sup>b</sup>		
PhenoAge	0.31 (4.48)	0.67 (5.42)	443	0.065	-0.29 (4.54)	-0.61 (5.04)	400	0.104 <sup>b</sup>		
GrimAge	1.11 (3.00)	1.50 (3.23)	443	< 0.001	-1.02 (2.73)	-1.34 (2.86)	400	0.004 <sup>b</sup>		
DunedinPACE (biol./chron.)	1.03 (0.11)	1.10 (0.12)	490	< 0.001	0.98 (0.10)	1.05 (0.11)	468	<0.001 <sup>b</sup>		
Sex hormone level <sup>a</sup>										
Estradiol (pmol/l)	84.00 (53.78)	97.40 (48.30)	495	< 0.001	9.20 (29.77)	9.20 (25.10)	487	0.786 <sup>c</sup>		
DHEAS (ng/ml)	1074.28 (847.38)	889.00 (699.0)	499	< 0.001	743.20 (682.27)	643.00 (604.80)	486	<0.001 <sup>c</sup>		
FAI	37.08 (13.99)	26.32 (9.91)	491	< 0.001	0.89 (1.19)	0.50 (0.82)	466	<0.001 <sup>c</sup>		

Table 2: Sex hormone level and DNAmAA estimators of participants who attended both baseline and follow-up assessments

Note. <sup>a</sup>=Median (Inter Quartile Range), <sup>b</sup>=paired t-test, <sup>c</sup>=Wilcoxon signed-rank test, Mdn=Median, IQR=Inter Quartile Range, SD=Standard Deviation, DNAmAA=DNA methylation age acceleration (years), FAI=Free Androgen Index, T0=Baseline assessment, T1=Follow-up assessment. A Wilcoxon signed-rank test was used to test for differences in median sex hormone concentration between baseline and follow-up assessment. To test for differences in mean DNAmAA a paired t-test was calculated. Only participants with available data at both time points are included in this table.

		Men							Women							
		N/ 11		0E	CI	CI	1			<u>ar</u>	CI	CI	1			
Hormone	DNAmAA	Model	Estimate	SE	LL	UL	p-value	n	Estimate	SE	LL	UL	p-value	n		
Estradiol	Horvath	1	0.007	0.005	-0.002	0.015	0.141	446	0.008	0.007	-0.006	0.022	0.288	406		
		2	0.004	0.005	-0.005	0.013	0.390	420	0.004	0.007	-0.010	0.019	0.571	384		
	GrimAge	1	0.001	0.003	-0.005	0.007	0.741	446	0.002	0.005	-0.008	0.011	0.740	406		
		2	0.002	0.003	-0.003	0.008	0.400	420	-0.004	0.005	-0.013	0.005	0.414	384		
	DunedinPACE	1	2.7E-5	1.1E-4	-1.9E-4	2.4E-4	0.802	483	-1.6E-4	1.7E-4	-4.9E-4	1.7E-4	0.346	464		
		2	6.6E-6	1.1E-4	-2.1E-4	2.2E-4	0.952	455	-3.6E-4	1.7E-4	-0.001	-3.0E-5	0.032	433		
DHEAS	Horvath	1	-4.8E-4	3.3E-4	-0.001	1.6E-4	0.144	449	-3.1E-4	4.0E-4	-0.001	5.E-4	0.441	405		
		2	-0.001	3.4E-4	-0.001	-6.2E-5	0.032	424	-4.3E-4	4.2E-4	-0.001	4.E-4	0.300	383		
	GrimAge	1	1.2E-4	2.3E-4	-3.3E-4	0.001	0.603	449	3.2E-4	2.6E-4	-2.E-4	0.001	0.219	405		
		2	-9.0E-5	2.1E-4	-0.001	3.3E-4	0.677	424	2.9E-4	2.5E-4	-2.1E-4	0.001	0.260	383		
	DunedinPACE	1	-1.8E-6	7.8E-6	-1.7E-5	1.3E-5	0.817	486	4.5E-6	9.5E-6	-1.E-5	2.E-5	0.637	464		
		2	-8.6E-7	7.8E-6	-1.6E-5	1.4E-5	0.912	459	1.2E-5	9.3E-6	-6.E-6	3.E-5	0.185	433		
FAI	Horvath	1	0.011	0.016	-0.021	0.043	0.503	444	-0.020	0.141	-0.297	2.6E-1	0.888	387		
		2	0.004	0.017	-0.029	0.038	0.799	418	-0.046	0.144	-0.328	0.237	0.751	367		
	GrimAge	1	-0.026	0.011	-0.049	-0.004	0.021	444	0.019	0.094	-0.166	0.203	0.842	387		
		2	-0.019	0.011	-0.041	0.002	0.072	418	0.028	0.088	-0.145	0.202	0.748	367		
	DunedinPACE	1	-0.001	4.E-4	-0.001	2.E-4	0.123	480	0.003	0.003	-0.004	0.009	0.382	443		
		2	-2.E-4	4.E-4	-0.001	0.001	0.613	452	0.001	0.003	-0.005	0.007	0.737	415		

Table 3: Multiple linear regression analyses of DNAmAA on estradiol, DHEAS and FAI for older participants of the BASE-II at baseline

Model 1: unadjusted; Model 2: adjusted for chronological age, smoking (pack years), alcohol (g/d), BMI. Note: DNAmAA=DNA methylation age

acceleration, SE=Standard Error, CI=Confidence Interval, LL=Lower Limit, UL=Upper Limit.

		Men							Women							
∆Hormone	ΔDNAmAA	N/ 11		<u>ar</u>	CI	CI	1	n	Estimate	SE	CI	CI	p-value			
		Model	Estimate	SE	LL	UL	p-value				LL	UL		n		
Estradiol	Horvath	1	-3.8E-4	0.004	-0.007	0.007	0.916	433	-0.001	0.004	-0.009	0.008	0.903	395		
		2	-0.001	0.004	-0.009	0.007	0.836	408	-0.002	0.004	-0.011	0.007	0.686	375		
	GrimAge	1	-0.004	0.003	-0.009	0.001	0.110	433	-0.001	0.003	-0.007	0.005	0.741	395		
		2	-0.002	0.003	-0.009	0.004	0.522	408	4.9E-4	0.004	-0.006	0.007	0.890	375		
	DunedinPACE	1	1.7E-5	8.2E-5	-1.4E-4	1.8E-4	0.832	472	-8.3E-5	9.2E-5	-2.6E-4	9.9E-5	0.371	455		
		2	9.5E-5	1.0E-4	-1.1E-4	3.0E-4	0.357	445	5.3E-5	1.1E-4	-1.6E-4	2.6E-4	0.620	424		
DHEAS	Horvath	1	9.1E-5	3.9E-4	-0.001	0.001	0.818	436	-8.5E-5	0.001	-0.001	0.001	0.874	394		
		2	2.6E-5	4.1E-4	-0.001	0.001	0.950	412	-1.6E-4	0.001	-0.001	0.001	0.757	374		
	GrimAge	1	-6.6E-5	2.9E-4	-0.001	0.001	0.822	436	-2.4E-4	3.9E-4	-0.001	0.001	0.542	394		
		2	-1.7E-4	3.2E-4	-0.001	4.6E-4	0.604	412	-3.8E-4	4.2E-4	-0.001	4.4E-4	0.361	374		
	DunedinPACE	1	-3.4E-5	8.7E-6	-5.1E-5	-1.7E-5	< 0.001	475	-2.7E-5	1.1E-5	-5.0E-5	-4.6E-6	0.018	455		
		2	-2.2E-5	9.6E-6	-4.1E-5	-3.2E-6	0.022	449	-3.4E-5	1.2E-5	-5.8E-5	-1.0E-5	0.005	424		
FAI	Horvath	1	-0.003	0.012	-0.027	0.021	0.794	430	-0.134	0.120	-0.370	0.101	0.263	377		
		2	-0.009	0.017	-0.042	0.024	0.605	405	-0.069	0.219	-0.499	0.361	0.752	359		
	GrimAge	1	-0.008	0.009	-0.026	0.010	0.374	430	-0.007	0.087	-0.179	0.164	0.932	377		
		2	-0.012	0.013	-0.038	0.014	0.359	405	0.109	0.171	-0.227	0.445	0.522	359		
	DunedinPACE	1	-3.6E-4	2.8E-4	-0.001	1.8E-4	0.189	468	0.003	0.003	-0.002	0.008	0.243	435		
		2	-2.6E-4	4.0E-4	-0.001	0.001	0.523	441	0.009	0.005	-0.001	0.019	0.071	407		

Table 4: Longitudinal multiple linear regression analyses of  $\Delta DNAmAA$  on  $\Delta estradiol$ ,  $\Delta DHEAS$  and  $\Delta FAI$  for older participants of the BASE-II

Model 1: unadjusted; Model 2: adjusted for chronological age at baseline, years since baseline assessment, baseline hormone concentration, baseline

DNAmAA, baseline smoking (pack years), alcohol (g/d), BMI. Note: DNAmAA=DNA methylation age acceleration, SE=Standard Error, CI=Confidence Interval, LL=Lower Limit, UL=Upper Limit.

Figure 1: Case selection and final analytic datasets. Selected participants of the Berlin Aging Study II (BASE-II) were reassessed on average after 7.3 years. If the number of participants varied due to differences in the availability of hormone or epigenetic clock data, the maximum number of observations was reported in this flow chart. Individual sample sizes are indicated with each statistical analysis.

